Voyager’s tau-targeted gene therapy VY-1706 gains IND approval

Voyager Therapeutics Inc. has obtained IND clearance from the FDA for VY-1706, the company’s investigational gene therapy targeting intracellular and extracellular tau for the treatment of Alzheimer’s disease.